Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma
1998

Immunotherapy with Low-Dose Interleukin 2 in Neuroblastoma

Sample size: 17 publication Evidence: moderate

Author Information

Author(s): A Pession, A Prete, F Locatelli, S Pierinelli, AL Pession, R Maccario, E Magrini, B De Bernardi, P Paolucci, G Paolucci

Primary Institution: Clinica Pediatrica, Osp. S. Orsola-Malpighi Universita di Bologna

Hypothesis

Can low doses of recombinant human interleukin 2 (rHuIL-2) effectively control minimal residual disease in children with neuroblastoma after high-dose chemotherapy and autologous stem cell transplantation?

Conclusion

Low doses of rHuIL-2 are well tolerated and can help control minimal residual disease in children with high-risk neuroblastoma after intensive treatment.

Supporting Evidence

  • 12 out of 17 patients are alive and well after treatment.
  • The 2-year event-free survival rate was 67%.
  • The overall survival rate was 92%.
  • Patients showed an increase in T lymphocytes and natural killer cells after treatment.

Takeaway

This study tested a medicine called interleukin 2 to help kids with a type of cancer called neuroblastoma feel better after strong treatments. It worked pretty well without making them too sick.

Methodology

Patients received low doses of rHuIL-2 after high-dose chemotherapy and autologous stem cell transplantation, with treatment monitored for safety and effectiveness.

Potential Biases

Potential bias due to lack of a control group.

Limitations

The study had a small sample size and was not randomized.

Participant Demographics

12 male and 5 female patients with a median age of 52 months.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication